Deb Kientop

Company: DEKA Biosciences

Job title: Vice President, Clinical Operations

Seminars:

Updating the Clinical Progress of DK210 (EGFR), Fusing IL-10 With wtIL-2 to Prevent Toxicity & Enhance Potency 11:00 am

Treating patients with cold tumors has already elicited potent peripheral immune activation leading to confirmed stable disease of stage 4 PDAC, and unconfirmed stable disease of patients with stage 4 CRC Indicating DK210 (EGFR) has successfully blunted IL-2 inflammatory toxicity while retaining potent immunological activation and dramatically improved its therapeutic index Outlining how responses stimulated…Read more

day: Conference Day One